Authors
Leyla Kara
Published in
Acta diabetologica. Jul 15, 2026. Epub Jul 15, 2026.
Abstract
Continuous glucose monitoring (CGM) use is associated with improved glycaemic outcomes and reduced hypoglycaemia in type 1 diabetes; however, access remains limited due to cost and reimbursement disparities.
This retrospective observational study included children and adolescents with type 1 diabetes followed in a single center. Clinical outcomes before and after reimbursement were compared using paired statistical analyses.
The implementation of the reimbursement policy in Türkiye was associated with improved access to diabetes technology through reduced financial barriers and with favourable changes in clinical outcomes. CGM usage increased significantly from 26% (n = 11) before reimbursement to 92% (n = 38) after reimbursement. A slight reduction in mean HbA1c levels was observed (from 9.08% to 8.99%). In children under 10 years of age, the proportion achieving target HbA1c levels (< 7%) increased from 16% to 33% (p = 0.042). In addition, a decreasing trend in hypoglycemia frequency and emergency department visits was observed following continuous glucose monitoring use.
The introduction of a national reimbursement policy was associated with a marked increase in access to CGM in children and adolescents with type 1 diabetes. However, changes in glycaemic outcomes were limited and not statistically significant in the overall cohort. These findings suggest that the primary impact of reimbursement was improved adoption of diabetes technology rather than substantial short-term improvement in glycaemic control. Further large-scale studies are needed to evaluate long-term clinical outcomes and patient-reported benefits.
PMID:
42455340
Bibliographic data and abstract were imported from PubMed on 15 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0